Academia, industry and the slow adoption of new treatments
Klein et al. discuss the academia-pharma industry gap and its impact on patient care, arguing that the severing of academic collaboration with industry has caused a drop in academic participation in clinical trials, delayed adoption of new treatments, and harmed patients. They suggest a patient-centred approach to academia-industry relations.
Authors
- Wolfgang Löscher (ORCID: https://orcid.org/0000-0002-9648-8973)
- Pavel Klein (ORCID: https://orcid.org/0000-0001-7244-3722)
- Josemir W. A. S. Sander (ORCID: https://orcid.org/0000-0001-6041-9661)
- Amanda W. Pong (ORCID: https://orcid.org/0000-0003-1349-3409)
- Matthias J. Koepp (ORCID: https://orcid.org/0000-0002-4277-8000)
- Edward Faught (ORCID: https://orcid.org/0000-0001-7415-8044)
Institutions
- Emory University (US)
- Sichuan University (CN)
- Epilepsy Research UK (GB)
- Medizinische Hochschule Hannover (DE)
- West China Hospital of Sichuan University (CN)
- Mid Atlantic Epilepsy and Sleep Center (US)
- University College London (GB)
- Epilepsy Society (GB)
Publication Details
- Journal
- Brain
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1093/brain/awaf295
- Primary Topic
- Pharmaceutical industry and healthcare
- Type
- article
- Field-Weighted Citation Impact
- 0.00